文献速递免疫规划传染病防控与疫情报告

6月龄至4岁婴幼儿SARS-CoV-2流行病学及COVID-19 mRNA疫苗有效性——新疫苗监测网络,美国,2022年7月至2023年9月

SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months-4 Years - New Vaccine Surveillance Network, United States, July 2022-September 2023.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2023-12-01

利用新疫苗监测网络的前瞻性人群监测数据,采用检测阴性病例对照设计,评估6月龄至4岁婴幼儿COVID-19 mRNA疫苗对急诊就诊和住院的保护效果。共纳入7,434名儿童,5%SARS-CoV-2检测阳性,95%阴性;86%未接种疫苗。与未接种任何疫苗相比,接种≥2剂COVID-19 mRNA疫苗预防急诊就诊和住院的有效性为40%(95%CI=8%-60%)。

要点

  • 6月龄至4岁儿童中,接种≥2剂COVID-19 mRNA疫苗预防急诊就诊和住院的有效性为40%(95%CI=8%-60%)。
  • 纳入的7,434名儿童中,86%未接种疫苗,4%接种1剂,10%接种≥2剂。
  • 研究结果支持现有推荐,即 young children 接种COVID-19疫苗以减少相关急诊就诊和住院。

核心结论

  • 与未接种任何疫苗相比,6月龄至4岁儿童接种≥2剂COVID-19 mRNA疫苗预防COVID-19相关急诊就诊和住院的有效性为40%(95%CI=8%-60%)。
  • 这些发现支持现有推荐,即年幼儿童接种COVID-19疫苗以减少COVID-19相关急诊就诊和住院。

研究设计与样本

  • 研究使用新疫苗监测网络(New Vaccine Surveillance Network)的前瞻性人群监测系统数据。
  • 采用检测阴性病例对照设计估计疫苗有效性,并描述2022年7月1日至2023年9月30日期间6月龄至4岁婴幼儿SARS-CoV-2的流行病学特征。
  • 共纳入7,434名儿童,其中5%SARS-CoV-2检测阳性,95%检测阴性;86%未接种疫苗,4%接种1剂任何疫苗产品,10%接种≥2剂。

主要发现

  • 在7,434名儿童中,5%收到SARS-CoV-2阳性检测结果,95%收到阴性检测结果。
  • 86%的儿童未接种疫苗,4%接种1剂任何疫苗产品,10%接种≥2剂。
  • 与未接种任何疫苗的儿童相比,接种≥2剂COVID-19 mRNA疫苗预防急诊就诊和住院的有效性为40%(95%CI=8%-60%)。

关键数值与推荐

  • 接种≥2剂COVID-19 mRNA疫苗相对于未接种任何疫苗,预防急诊就诊和住院的有效性为40%(95%CI=8%-60%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SARS-CoV-2 infection in young children is often mild or asymptomatic; however, some children are at risk for severe disease. Data describing the protective effectiveness of COVID-19 mRNA vaccines against COVID-19-associated emergency department (ED) visits and hospitalization in this population are limited. Data from the New Vaccine Surveillance Network, a prospective population-based surveillance system, were used to estimate vaccine effectiveness using a test-negative, case-control design and describe the epidemiology of SARS-CoV-2 in infants and children aged 6 months-4 years during July 1, 2022-September 30, 2023. Among 7,434 children included, 5% received a positive SARS-CoV-2 test result, and 95% received a negative test result; 86% were unvaccinated, 4% had received 1 dose of any vaccine product, and 10% had received ≥2 doses. When compared with receipt of no vaccines among children, receipt of ≥2 COVID-19 mRNA vaccine doses was 40% effective (95% CI = 8%-60%) in preventing ED visits and hospitalization. These findings support existing recommendations for COVID-19 vaccination of young children to reduce COVID-19-associated ED visits and hospitalization.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Tannis A, Englund JA, Perez A, et al. SARS-CoV-2 Epidemiology and COVID-19 mRNA Vaccine Effectiveness Among Infants and Children Aged 6 Months-4 Years - New Vaccine Surveillance Network, United States, July 2022-September 2023. MMWR Morb Mortal Wkly Rep. 2023. PMID: 38032834. doi:10.15585/mmwr.mm7248a2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。